Efranat Ltd develops a unique anti-cancer immunotherapy treatment based on a natural plasma protein molecule.
The concept underlying the technology is to engage the body's own immune system and harness it against cancer.
Efranat's product is a very potent immunomodulator that activates macrophages, a group of white blood cells that play key role in the innate immune system’s defense against cancer.
The product is manufactured and processed under GMP in a procedure that mimics the natural process in the body .
Treatment of dogs with spontaneous tumors shows promising results.
Efranat is currently conducting human Phase 1 clinical trial in cancer patients with advanced solid tumors at Sheba hospital.
Efranat's product was manufactured under cGMP at Kamada Ltd.Kamada, founded in 1990, is a biopharmaceutical company engaged in developing, producing and marketing specialty life-saving therapeutics.
Kamada specializes in protein purification technology from human plasma, using unique methods
Phase 1 study
Efranat is currently conducting a Phase 1 study at "Sheba" hospital. This study is open label, dose-escalation trial aiming to evaluate the safety and tolerability of Efranat's product in subjects with advanced solid malignancies. Study population will consist of up to 48 male or female participants, ages 18-80, diagnosed with inoperable, recurrent or metastatic malignant solid tumors, deemed incurable, and who have failed to respond to standard therapy or for whom no standard therapy is available.For more details about the Clinical trial click here